Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Hologic upgraded to Buy at Needham following CYNO deal; tgt $46 (39.03)Needham upgrades HOLX to Buy from Hold and sets target price at $46. Firm's upgrade comes after HOLX announced the acquisition of Cynosure (<strong>CYNO</strong>) for $1.44B with an all-cash tender offer. CYNO is a leading aesthetics company that competes in a $2B market growing in the double-digits with a range of products used for hair removal, body contouring, skin revitalization, and other cosmetic procedures. HOLX expects CYNO to increase its rev growth and add $0.13-0.15 to its FY18E EPS. HOLX has now effectively swapped a business with declining sales and margins (blood screening) for one with double-digit growth and improving margins (CYNO). With the blood screening EPS «hole» now partially filled and HOLX facing increasingly easy comps over the next three quarters, they upgrade to Buy.</td> </tr></table>"